Search - tctmd.com

Displaying 1 - 8 of 8

Sort: Relevancy | Date

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

News Conference News ACC 2023

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Todd Neale

March 05, 2023

Presentation ACC 2022

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

Presenter: Duk-Woo Park

April 04, 2022

Presentation ACC 2022

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Presenter: Michael J. Reardon

April 04, 2022

News Conference News ACC 2022

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Michael O'Riordan

April 04, 2022

News Conference News ACC 2021

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

Todd Neale

May 15, 2021

News Conference News ACC 2020

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

L.A. McKeown

April 07, 2020

Advertisement

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Self-Expanding TAVI Holds Up to Surgery Out to 3 Years in Low-Risk Patients

Edoxaban Versus Dual Antiplatelet Therapy For Valve Thrombosis And Cerebral Thromboembolism After Transcatheter Aortic-valve Replacement: A Randomized ADAPT-TAVR Trial

5-Year Incidence, Outcomes and Predictors of Structural Valve Deterioration of Transcatheter and Surgical Aortic Bioprostheses: Insights from the CoreValve US Pivotal and SURTAVI Trials

Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years

Occluding the LAA During Surgery Lowers Stroke Risk: LAAOS III

Edoxaban May Be Alternative to Warfarin After Surgical Valve Implantation or Repair

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content